Articles

Podcasts

Videos

Clinical

“It’s time to ensure widespread availability by promoting access to safe, effective, and sustainably priced medications, rather than providing incentives to prescribe higher-cost alternatives,” the authors said. 

An Unintended Consequence for High HIV Drug Prices 

Joined by Steven Wolfe, DO, MPH, and Stuart A Fisk, CRNP, of the Allegheny Health Network, we discuss the populations most at risk of HIV infection, as well as advice for making healthcare spaces more inclusive and accessible for LGBTQ+ people.

Episode 5: “A Social and Political Pandemic”: HIV Disparities in LGBTQ+ People

Findings highlight need for innovative prevention strategies, experts say.

Public Health Watch: New CDC Surveillance Report Documents Continued Rise in Some STDs

Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.

First In-Africa Clinical Trial of mRNA HIV Vaccine 

In Part 2 of a video interview, Sornana Segal-Maurer, MD, discusses the newly published research findings that detail the potential of lenacapavir.

“Part of the Lenacapavir Story”: Expanding Treatments to People with Multidrug-Resistant HIV

Could lenacapavir be the answer for people with multidrug-resistant HIV infection? Principal investigator Sorana Segal-Maurer discusses the promising trial results in this challenging cohort (Interview part 1).

Lenacapavir for HIV Infection in a Multidrug-Resistant Study Cohort

In a study of 32 patients with fourth-line metastatic colorectal cancer, the HIV drug lamivudine slowed disease progression in a quarter of participants. 

HIV Drug Slows Colorectal Cancer Disease Progression 

Two other male patients were previously known to be in HIV remission, but this is the first woman and first cord blood stem cell transplant case. 

Woman Achieves HIV Remission after Cord Blood Stem Cell Transplant

HIV reservoirs can remain dormant, reigniting infection at an opportune moment. New strategies seek to reignite these viral reservoirs so they can be identified and destroyed by the immune system.

Novel Strategies to Identify and Eliminate Latent HIV Cells

PrEP prescription initiations and fills dropped during the early parts of the COVID-19 pandemic, according to investigators from the NY State Department of Health. 

SEXUALLY TRANSMITTED DISEASES

Latest News